CRISPR Atlas

Companies

Public and private organisations building gene-editing medicines, tools and platforms.

17 companies in the Atlas.

17 표시됨

기업	티커	본사	설립연도	플랫폼	주요 단계
CRISPR Therapeutics Co-founded by Emmanuelle Charpentier, and the company behind the first approved…	CRSP Nasdaq	Zug, Switzerland	2013	CRISPR-Cas9 platform	Approved
Intellia Therapeutics Co-founded by Jennifer Doudna, and the company that first delivered CRISPR into…	NTLA Nasdaq	Cambridge, Massachusetts	2014	In vivo CRISPR platform	Phase III
Beam Therapeutics Founded by David Liu and colleagues to commercialise base editing — precision…	BEAM Nasdaq	Cambridge, Massachusetts	2017	Base editing platform	Phase III
Editas Medicine One of the first CRISPR companies, which discontinued its cell-therapy and eye…	EDIT Nasdaq	Cambridge, Massachusetts	2013	In vivo editing	Preclinical
Prime Medicine Founded to commercialise prime editing, and the company behind the first…	PRME Nasdaq	Cambridge, Massachusetts	2019	Prime editing platform	Phase I/II
Verve Therapeutics Built to turn heart disease into a one-time treatment, and acquired by Eli…	—	Boston, Massachusetts	2018	In vivo base editing	Phase II
Caribou Biosciences Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make…	CRBU Nasdaq	Berkeley, California	2011	Cell therapy	Phase I
Sana Biotechnology Engineering transplanted cells to be invisible to the immune system, so they…	SANA Nasdaq	Seattle, Washington	2018	Cell engineering	Phase I
Scribe Therapeutics Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather…	—	Alameda, California	2018	Engineered editors	Preclinical
Mammoth Biosciences Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough…	—	Brisbane, California	2017	Miniature editors and diagnostics	Preclinical
Arbor Biotechnologies Co-founded by Feng Zhang and David Scott to discover new editing enzymes from…	—	Cambridge, Massachusetts	2016	Novel editors	Phase I
Vertex Pharmaceuticals The established biotechnology company that partnered on, and commercialises…	VRTX Nasdaq	Boston, Massachusetts	1989	Large biotechnology	Approved
bluebird bio A pioneer of lentiviral gene addition with several approved therapies — and a…	—	Somerville, Massachusetts	—	Gene addition	Approved
Tessera Therapeutics Developing 'gene writing' — mobile genetic elements repurposed to insert whole…	—	Somerville, Massachusetts	2018	Gene writing	Preclinical
Tune Therapeutics Turning genes up and down without changing sequence — epigenetic editing taken…	—	Durham, North Carolina	2021	Epigenetic editing	Phase I
Sangamo Therapeutics The company that took gene editing into humans first, years before CRISPR…	SGMO Nasdaq	Richmond, California	1995	Zinc finger platform	Phase III
Eli Lilly and Company A major pharmaceutical company that entered gene editing by acquisition, buying…	LLY NYSE	Indianapolis, Indiana	1876	Large pharmaceutical	Phase II

"주요 단계"는 해당 기업의 프로그램 중 가장 앞선 단계를 나타내며, 기업에 대한 평가가 아닙니다. 비상장 기업에는 티커가 표시되지 않습니다. 수치는 기업 공시 자료에서 가져오며, 각 기업 페이지에 날짜가 표기되어 있습니다.

투자 조언이 아닙니다 기업 정보는 교육 및 연구 목적으로 작성되었습니다. 이 내용은 어떠한 증권의 매수·매도·보유를 권장하는 것이 아닙니다. 전체 면책 조항 →